- Details
- Weranja Ranasinghe discusses research on developing an immunohistochemistry (IHC) profile to predict response to BCG in non-muscle invasive bladder cancer (NMIBC). In this pilot study analyzing matched BCG responders and non-responders, Dr. Ranasinghe and his team observed that the most meaningful distinctions were not in absolute immune marker levels, but in their ratios. Non-responders demonstra...
|
- Details
- Ashish Kamat moderates a discussion with Paolo Gontero and Maria Carmen Mir addressing management approaches for BCG-unresponsive bladder cancer. Dr. Gontero highlights the limited treatment options in Europe compared to the US, noting that after gemcitabine-docetaxel failure, European physicians face significant constraints without access to newer immunotherapies. Dr. Mir emphasizes that 96% of p...
|
- Details
- Zachary Klaassen interviews Sarah Psutka about prehabilitation in urologic oncology. Dr. Psutka discusses how exercise interventions before, during, and after cancer treatment can significantly improve patient outcomes, emphasizing that only about 7% of cancer patients currently meet recommended activity guidelines. She outlines her "Ps of prehab" approach—making exercise personalized, pragmatic,...
|
- Details
- Leslie Ballas speaks with Jeannie Hoffman-Censits and Armine Smith about gender disparities in bladder cancer care. Drs. Smith and Hoffman-Censits highlight how women often face delayed diagnoses because their hematuria symptoms are frequently dismissed as UTIs, requiring multiple provider visits before reaching a urologist. They note that women are commonly diagnosed at later stages, limiting tre...
|
- Details
- Ashish Kamat speaks with Marco Moschini about expanding active surveillance criteria for recurrent low-grade bladder cancer. Dr. Moschini presents his single-center retrospective study from San Raffaele Hospital analyzing outcomes among intermediate-risk non-muscle invasive bladder cancer patients based on IBCG risk stratification. These findings demonstrate that patients with zero risk factors ac...
|
- Details
- Zachary Klaassen speaks with Trinity Bivalacqua about updated results from the BOND-003 Cohort C phase III trial examining cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Dr. Bivalacqua presents efficacy data showing a 75.5% overall complete response rate, with 46% maintaining complete response at 12 months and an estimated 6...
|
- Details
- Ashish Kamat hosts Bogdana Schmidt to discuss the evolving landscape of non-muscle invasive bladder cancer treatment. Dr. Schmidt presents a comprehensive overview of risk stratification approaches, highlighting how BCG—despite being the cornerstone treatment for high-risk disease for over 50 years—has significant limitations including side effects, intense treatment schedules, and a 30-40% recurr...
|
- Details
- Alicia Morgans discusses the LEGEND trial with John Taylor, focusing on detalimogene voraplasmid (EG-70) for BCG-refractory non-muscle invasive bladder cancer. Dr. Taylor explains that EG-70 is a non-viral vector drug stimulating both innate and adaptive immune responses through the RIG-I pathway and interleukin 12 enhancement. The phase II trial has enrolled 21 patients in cohort 1 (BCG-refractor...
|
- Details
- Zachary Klaassen speaks with Sandip Prasad about the ENVISION trial investigating UGN-102 for primary chemo ablation of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Dr. Prasad explains this approach that treats tumors directly rather than using traditional TURBT followed by adjuvant therapy. The trial demonstrates impressive results with a 79.6% complete response rate...
|
- Details
- Ashish Kamat speaks with Lars Dyrskjøt about work from the UROMOL Consortium on comprehensive molecular analysis of non-muscle invasive bladder cancer (NMIBC). Dr. Dyrskjøt describes research incorporating whole exome sequencing, shallow whole genome sequencing, and total RNA sequencing of 438 tumor samples. Their findings reveal distinct genomic landscapes with 33 significantly mutated genes acro...
|
